RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
HanX Biopharma, a China oncology company, in-licensed China rights to a Phase III candidate for myelodysplastic syndromes from Onconova in a $51.5 million agreement. HanX agreed to pay $4 million upfront ($2 million fee and $2 million investment) plus put $2 million in escrow for China clinical development of rigosertib in patients with MDS. It will also pay Onconova up to $45.5 million in regulatory and sales milestones. In addition, HanX expects to test rigosertib together with its PD-1 antibody, now in China Phase II/III clinical trials.
Source: China Biotoday
